Sept. 15, 2025
| Today’s news and insights for biopharma leaders
A two-day meeting could prove an inflection point in HHS Secretary’s Kennedy’s efforts to overhaul U.S. vaccine policy, as hand-picked advisers are set to vote on guidelines for measles, hepatitis B and COVID shots.
|
The company’s new partnership with the "molecular glue” drug developer is broad, focused on immunology and could be worth up to $5.7 billion.
|
The company’s market value was largely wiped out after a therapy it’s been developing for pulmonary sarcoidosis missed its main study goal.
|
Biomanufacturers face complex buffer prep choices. This framework supports evaluating hybrid strategies using criteria to guide smarter, flexible decision-making.
|
From Our Library
Trendline
Supported by Bio-Rad
|
Playbook
Custom content for PharmaForceIQ
|
Trendline
Supported by EVERSANA
|
Trendline
Supported by 10x Genomics
|
Playbook
Custom content for Evaluate
|
View all resources
What We’re Reading
| 
